Equity Overview
Price & Market Data
Price: $4.42
Daily Change: -$0.16 / 3.62%
Range: $4.41 - $4.63
Market Cap: $717,494,464
Volume: 1,966,290
Performance Metrics
1 Week: -11.29%
1 Month: -13.18%
3 Months: -2.40%
6 Months: 25.49%
1 Year: 84.36%
YTD: 32.15%
Company Details
Employees: 394
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.